- Molecular NameNimodipine
- SynonymNimodipino [INN-Spanish]; Nimodipinum [INN-Latin]
- Weight376.365
- Drugbank_IDDB00393
- ACS_NO66085-59-4
- Show 2D model
- LogP (experiment)4.18
- LogP (predicted, AB/LogP v2.0)2.99
- pkaN/A
- LogD (pH=7, predicted)0.47
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.7
- LogSw (predicted, AB/LogsW2.0)0.01
- Sw (mg/ml) (predicted, ACD/Labs)0.23
- No.of HBond Donors2
- No.of HBond Acceptors9
- No.of Rotatable Bonds8
- TPSA133.69
- StatusFDA approved
- AdministrationIntravenous, Oral
- PharmacologyA dihydropyridine calcium channel blocker originally developed for the treatment of high blood pressure. It is not frequently used for this indication, but has shown good results in preventing a major complication of subarachnoid hemorrhage (a form of cerebral hemorrhage) termed vasospasm; this is now the main use of nimodipine.
- Absorption_value100.0
- Absorption (description)In humans, it is administered primarily orally and reaches peak plasma concentrations within one and a half hours.
- Caco_2N/A
- Bioavailability10.0
- Protein binding98.0
- Volume of distribution (VD)0.9 to 2.3 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmNimodipine is metabolized in the first pass metabolism. The dihydropyridine ring of the nimodipine is dehydrogenated in the hepatic cells of the liver, a process governed by Cytochrome P-4503A (CYP3A). This can be completely inhibited however, by troleandomycin (an antibiotic) or ketoconazole (an antifungal drug).
- Half life9 h (with initial rapid phase with half-life around 1 to 2 h).
- ExcretionStudies in non-human mammals using radioactive labeling have found that 40-50% of the dose is excreted via urine. The residue level in the body was never more than 1.5% in monkeys. There were some metabolites of the drug found in the milk of lactating rat subjects.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A